Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia

Joan H. Schiller, Paul Rasmussen, A. B. Benson, Robert S. Witte, Richard S. Bockman, Harold A. Harvey, Ethel S. Siris, Dennis L. Citrin, F. Anthony Greco, John L. Stock

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, >11.5 mg/dL [>2.87 mmol/L]). Ten (40%) of 25 etidronate-treated patients and 17 (46%) of 37 placebo-treated patients had recurrence of hypercalcemia within 150 days. Although patients taking etidronate had a longer time to the development of hypercalcemia (median, 55 days vs 28 days), this was not significantly different from the control group. The high attrition rate in this trial from hypercalcemia and other malignancy-related causes represents a major difficulty in conducting studies with agents that may require prolonged administration before producing a therapeutic effect.

Original languageEnglish (US)
Pages (from-to)963-966
Number of pages4
JournalArchives of Internal Medicine
Volume147
Issue number5
DOIs
StatePublished - 1987

Fingerprint

Etidronic Acid
Hypercalcemia
Maintenance
Neoplasms
Placebos
Recurrence
Therapeutic Uses
Calcium
Control Groups
Serum

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Schiller, J. H., Rasmussen, P., Benson, A. B., Witte, R. S., Bockman, R. S., Harvey, H. A., ... Stock, J. L. (1987). Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia. Archives of Internal Medicine, 147(5), 963-966. https://doi.org/10.1001/archinte.1987.00370050155026

Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia. / Schiller, Joan H.; Rasmussen, Paul; Benson, A. B.; Witte, Robert S.; Bockman, Richard S.; Harvey, Harold A.; Siris, Ethel S.; Citrin, Dennis L.; Greco, F. Anthony; Stock, John L.

In: Archives of Internal Medicine, Vol. 147, No. 5, 1987, p. 963-966.

Research output: Contribution to journalArticle

Schiller, JH, Rasmussen, P, Benson, AB, Witte, RS, Bockman, RS, Harvey, HA, Siris, ES, Citrin, DL, Greco, FA & Stock, JL 1987, 'Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia', Archives of Internal Medicine, vol. 147, no. 5, pp. 963-966. https://doi.org/10.1001/archinte.1987.00370050155026
Schiller, Joan H. ; Rasmussen, Paul ; Benson, A. B. ; Witte, Robert S. ; Bockman, Richard S. ; Harvey, Harold A. ; Siris, Ethel S. ; Citrin, Dennis L. ; Greco, F. Anthony ; Stock, John L. / Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia. In: Archives of Internal Medicine. 1987 ; Vol. 147, No. 5. pp. 963-966.
@article{881663769c2544e9ad97dd123308b2e6,
title = "Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia",
abstract = "Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, >11.5 mg/dL [>2.87 mmol/L]). Ten (40{\%}) of 25 etidronate-treated patients and 17 (46{\%}) of 37 placebo-treated patients had recurrence of hypercalcemia within 150 days. Although patients taking etidronate had a longer time to the development of hypercalcemia (median, 55 days vs 28 days), this was not significantly different from the control group. The high attrition rate in this trial from hypercalcemia and other malignancy-related causes represents a major difficulty in conducting studies with agents that may require prolonged administration before producing a therapeutic effect.",
author = "Schiller, {Joan H.} and Paul Rasmussen and Benson, {A. B.} and Witte, {Robert S.} and Bockman, {Richard S.} and Harvey, {Harold A.} and Siris, {Ethel S.} and Citrin, {Dennis L.} and Greco, {F. Anthony} and Stock, {John L.}",
year = "1987",
doi = "10.1001/archinte.1987.00370050155026",
language = "English (US)",
volume = "147",
pages = "963--966",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Maintenance Etidronate in the Prevention of Malignancy-Associated Hypercalcemia

AU - Schiller, Joan H.

AU - Rasmussen, Paul

AU - Benson, A. B.

AU - Witte, Robert S.

AU - Bockman, Richard S.

AU - Harvey, Harold A.

AU - Siris, Ethel S.

AU - Citrin, Dennis L.

AU - Greco, F. Anthony

AU - Stock, John L.

PY - 1987

Y1 - 1987

N2 - Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, >11.5 mg/dL [>2.87 mmol/L]). Ten (40%) of 25 etidronate-treated patients and 17 (46%) of 37 placebo-treated patients had recurrence of hypercalcemia within 150 days. Although patients taking etidronate had a longer time to the development of hypercalcemia (median, 55 days vs 28 days), this was not significantly different from the control group. The high attrition rate in this trial from hypercalcemia and other malignancy-related causes represents a major difficulty in conducting studies with agents that may require prolonged administration before producing a therapeutic effect.

AB - Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, >11.5 mg/dL [>2.87 mmol/L]). Ten (40%) of 25 etidronate-treated patients and 17 (46%) of 37 placebo-treated patients had recurrence of hypercalcemia within 150 days. Although patients taking etidronate had a longer time to the development of hypercalcemia (median, 55 days vs 28 days), this was not significantly different from the control group. The high attrition rate in this trial from hypercalcemia and other malignancy-related causes represents a major difficulty in conducting studies with agents that may require prolonged administration before producing a therapeutic effect.

UR - http://www.scopus.com/inward/record.url?scp=84942003437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942003437&partnerID=8YFLogxK

U2 - 10.1001/archinte.1987.00370050155026

DO - 10.1001/archinte.1987.00370050155026

M3 - Article

AN - SCOPUS:84942003437

VL - 147

SP - 963

EP - 966

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 5

ER -